Nicholls Stephen J, Tuzcu E Murat, Nissen Steven E
Department of Cardiovascular Medicine, Cleveland Clinic, Mail Code JJ-65, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Curr Atheroscler Rep. 2007 Oct;9(4):266-73. doi: 10.1007/s11883-007-0032-5.
Lowering low-density lipoprotein cholesterol is the cornerstone of risk modification in patients with established coronary artery disease. Considerable attention is currently focused on developing pharmacologic agents that promote the biologic activity of high-density lipoprotein. Advances in imaging of the artery wall provide the opportunity to evaluate the impact of medical therapies on serial changes in plaque burden. A number of reports describe the favorable effects of interventions that lower low-density lipoprotein cholesterol or promote the biologic activity of high-density lipoprotein. The current state of evidence defining the relative contribution of changes in plasma lipids on the tendency to plaque regression is reviewed.
降低低密度脂蛋白胆固醇是已确诊冠心病患者风险修正的基石。目前，大量关注集中在研发能促进高密度脂蛋白生物活性的药物制剂上。动脉壁成像技术的进展为评估药物治疗对斑块负荷系列变化的影响提供了契机。许多报告描述了降低低密度脂蛋白胆固醇或促进高密度脂蛋白生物活性的干预措施的有利作用。本文综述了界定血浆脂质变化对斑块消退倾向相对贡献的现有证据状况。
